TY - JOUR
T1 - Improved Diagnosis of Rare Disease Patients through Systematic Detection of Runs of Homozygosity
AU - RD–Connect Genome-Phenome Analysis Platform and URD-Cat Data Contributors
AU - Matalonga, Leslie
AU - Laurie, Steven
AU - Papakonstantinou, Anastasios
AU - Piscia, Davide
AU - Mereu, Elisabetta
AU - Bullich, Gemma
AU - Thompson, Rachel
AU - Horvath, Rita
AU - Pérez-Jurado, Luis
AU - Riess, Olaf
AU - Gut, Ivo
AU - van Ommen, Gert Jan
AU - Lochmüller, Hanns
AU - Beltran, Sergi
AU - Renieri, Alessandra
AU - Dursun, Ali
AU - Matilla-Duenas, Antoni
AU - Cormand, Bru
AU - Rivolta, Carlo
AU - Ayuso, Carmen
AU - Espinós, Carmen
AU - Scerri, Christian
AU - Yalnizoglu, Dilek
AU - Soler, Doriette
AU - Morava, Eva
AU - Barbetti, Fabrizio
AU - Forzano, Francesca
AU - Mari, Francesca
AU - Muntoni, Francesco
AU - Tort, Frederic
AU - Houlden, Henry James
AU - Tejada, Maria Isabel
AU - Senderek, Jan
AU - Benitez, Javier
AU - De La Calle, Javier Corral
AU - Serra, Jordi
AU - Millán, José Ma
AU - Segovia, Jose
AU - Gimeno Blanes, Juan Ramon
AU - Armstrong, Judith
AU - Ozgul, Koksal
AU - Vilarinho, Laura
AU - Montoliu, Lluis
AU - Posada, Manuel
AU - Mencarelli, Maria Antonietta
AU - Mora, Marina
AU - Bianchi, Paola
AU - Seeman, Pavel
AU - Elliott, Perry M.
AU - Ferlini, Alessandra
N1 - Funding Information:
Supported by European Union projects RD-Connect, Solve-RD, and European Joint Programme of Rare Diseases (EJP-RD) grants FP7 305444 , H2020 779257 , and H2020 825575 ; Instituto de Salud Carlos III grants PT13/0001/0044 and PT17/0009/0019 ; Instituto Nacional de Bioinformática ; ELIXIR Implementation Studies; European Union projects BBMRI-LPC EU FP7 313010, NeurOmics EU FP7 305121, and Undiagnosed Rare Disease Program of Catalonia ( Departament de Salut, Generalitat de Catalunya SLT002/16/00174 ); Canadian Institutes of Health Research Foundation grant FDN-167281 (H.L.); the European Research Council 309548 (R.H.); the Wellcome Investigator Award 109915/Z/15/Z (R.H.); the Medical Research Council (United Kingdom) MR/N025431/1 (R.H.); the Wellcome Trust Pathfinder Scheme 201064/Z/16/Z (R.H. and H.L.); the Newton Fund (United Kingdom/Turkey) MR/N027302/1 (R.H. and H.L.); the Spanish Ministry of Economy, Industry and Competitiveness to the European Molecular Biology Laboratory ( EMBL ) partnership; the Centro de Excelencia Severo Ochoa; the Centres de Recerca de Catalunya (CERCA) Program/ Generalitat de Catalunya ; the Generalitat de Catalunya through the Department of Health and Department of Business and Knowledge; the Spanish Ministry of Economy, Industry and Competitiveness with funds from the European Regional Development Fund corresponding to the 2014 to 2020 Smart Growth Operating Program.
Funding Information:
Supported by European Union projects RD-Connect, Solve-RD, and European Joint Programme of Rare Diseases (EJP-RD) grants FP7 305444, H2020 779257, and H2020 825575; Instituto de Salud Carlos III grants PT13/0001/0044 and PT17/0009/0019; Instituto Nacional de Bioinform?tica; ELIXIR Implementation Studies; European Union projects BBMRI-LPC EU FP7 313010, NeurOmics EU FP7 305121, and Undiagnosed Rare Disease Program of Catalonia (Departament de Salut, Generalitat de Catalunya SLT002/16/00174); Canadian Institutes of Health Research Foundation grant FDN-167281 (H.L.); the European Research Council 309548 (R.H.); the Wellcome Investigator Award 109915/Z/15/Z (R.H.); the Medical Research Council (United Kingdom) MR/N025431/1 (R.H.); the Wellcome Trust Pathfinder Scheme 201064/Z/16/Z (R.H. and H.L.); the Newton Fund (United Kingdom/Turkey) MR/N027302/1 (R.H. and H.L.); the Spanish Ministry of Economy, Industry and Competitiveness to the European Molecular Biology Laboratory (EMBL) partnership; the Centro de Excelencia Severo Ochoa; the Centres de Recerca de Catalunya (CERCA) Program/Generalitat de Catalunya; the Generalitat de Catalunya through the Department of Health and Department of Business and Knowledge; the Spanish Ministry of Economy, Industry and Competitiveness with funds from the European Regional Development Fund corresponding to the 2014 to 2020 Smart Growth Operating Program.
Publisher Copyright:
© 2020 Association for Molecular Pathology and American Society for Investigative Pathology
PY - 2020/9
Y1 - 2020/9
N2 - Autozygosity is associated with an increased risk of genetic rare disease, thus being a relevant factor for clinical genetic studies. More than 2400 exome sequencing data sets were analyzed and screened for autozygosity on the basis of detection of >1 Mbp runs of homozygosity (ROHs). A model was built to predict if an individual is likely to be a consanguineous offspring (accuracy, 98%), and probability of consanguinity ranges were established according to the total ROH size. Application of the model resulted in the reclassification of the consanguinity status of 12% of the patients. The analysis of a subset of 79 consanguineous cases with the Rare Disease (RD)–Connect Genome-Phenome Analysis Platform, combining variant filtering and homozygosity mapping, enabled a 50% reduction in the number of candidate variants and the identification of homozygous pathogenic variants in 41 patients, with an overall diagnostic yield of 52%. The newly defined consanguinity ranges provide, for the first time, specific ROH thresholds to estimate inbreeding within a pedigree on disparate exome sequencing data, enabling confirmation or (re)classification of consanguineous status, hence increasing the efficiency of molecular diagnosis and reporting on secondary consanguinity findings, as recommended by American College of Medical Genetics and Genomics guidelines.
AB - Autozygosity is associated with an increased risk of genetic rare disease, thus being a relevant factor for clinical genetic studies. More than 2400 exome sequencing data sets were analyzed and screened for autozygosity on the basis of detection of >1 Mbp runs of homozygosity (ROHs). A model was built to predict if an individual is likely to be a consanguineous offspring (accuracy, 98%), and probability of consanguinity ranges were established according to the total ROH size. Application of the model resulted in the reclassification of the consanguinity status of 12% of the patients. The analysis of a subset of 79 consanguineous cases with the Rare Disease (RD)–Connect Genome-Phenome Analysis Platform, combining variant filtering and homozygosity mapping, enabled a 50% reduction in the number of candidate variants and the identification of homozygous pathogenic variants in 41 patients, with an overall diagnostic yield of 52%. The newly defined consanguinity ranges provide, for the first time, specific ROH thresholds to estimate inbreeding within a pedigree on disparate exome sequencing data, enabling confirmation or (re)classification of consanguineous status, hence increasing the efficiency of molecular diagnosis and reporting on secondary consanguinity findings, as recommended by American College of Medical Genetics and Genomics guidelines.
UR - http://www.scopus.com/inward/record.url?scp=85087791154&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087791154&partnerID=8YFLogxK
U2 - 10.1016/j.jmoldx.2020.06.008
DO - 10.1016/j.jmoldx.2020.06.008
M3 - Article
C2 - 32619640
AN - SCOPUS:85087791154
SN - 1525-1578
VL - 22
SP - 1205
EP - 1215
JO - Journal of Molecular Diagnostics
JF - Journal of Molecular Diagnostics
IS - 9
ER -